By a News Reporter-Staff News Editor at Cancer Gene Therapy Week -- Current study results on Biotechnology have been published. According to news reporting originating from Hangzhou, People's Republic of China, by NewsRx correspondents, research stated, "Long non-coding RNA HOTAIR exerts regulatory functions in various biological processes in cancer cells, such as proliferation, apoptosis, mobility, and invasion. We previously found that HOX transcript antisense RNA (HOTAIR) is a negative prognostic factor and exhibits oncogenic activity in hepatocellular carcinoma (HCC)."
Our news editors obtained a quote from the research from Zhejiang University, "In this study, we aimed to investigate the role and molecular mechanism of HOTAIR in promoting HCC cell migration and invasion. Firstly, we profiled its gene expression pattern by microarray analysis of HOTAIR loss in Bel-7402 HCC cell line. The results showed that 129 genes were significantly down-regulated, while 167 genes were significantly up-regulated (fold change >2, pBioinformatics analysis indicated that RNA binding proteins were involved in this biological process. HOTAIR suppression using RNAi strategy with HepG2 and Bel-7402 cells increased the mRNA and protein expression levels of RNA binding motif protein 38 (RBM38). Moreover, the expression levels of RBM38 in HCC specimens were significantly lower than paired adjacent noncancerous tissues. In addition, knockdown of HOTAIR resulted in a decrease of cell migration and invasion, which could be specifically rescued by down-regulation of RBM38."
According to the news editors, the research concluded: "Taken together, HOTAIR could promote migration and invasion of HCC cells by inhibiting RBM38, which indicated critical roles of HOTAIR and RBM38 in HCC progression."
For more information on this research see: Long non-coding RNA HOTAIR promotes cell migration and invasion via down-regulation of RNA binding motif protein 38 in hepatocellular carcinoma cells. International Journal of Molecular Sciences, 2014;15(3):4060-76 (see also Biotechnology).
The news editors report that additional information may be obtained by contacting C. Ding, Division of Hepatobiliary and Pancreatic Surgery, Dept. of Surgery, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, Zhejiang, People's Republic of China. Additional authors for this research include S. Cheng, Z. Yang, Z. Lv, H. Xiao, C. Du, C. Peng, H. Xie, L. Zhou, J. Wu and S. Zheng.
Keywords for this news article include: Asia, Biotechnology, Hangzhou, Genetics, Oncology, Cancer Gene Therapy, Hepatocellular Carcinoma, People's Republic of China.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC